Tobramycin (TOBI Podhaler®)

Assessment Status Rapid Review Complete
Drug Tobramycin
Brand TOBI Podhaler®
Indication For the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF.
Assessment Process
Rapid review commissioned 03/11/2010
Rapid review completed 29/11/2010
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended